Andy Bonnett has been dealing with drug-resistant lung cancer since 2008, but has benefited from clinical trials studying new therapies.
Bonnett has had to deal with further shifts in his cancer makeup and treatment. Last summer, his tumors began showing signs of resistance to Xalkori. He started to feel a return of the pain that marked his original disease. After returning from a kayaking trip for people with cancer, Bonnett underwent new scans, which revealed multiple lesions.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.